Eli Lilly and Company (LLY)
| Market Cap | 685.14B |
| Revenue (ttm) | 53.26B |
| Net Income (ttm) | 13.80B |
| Shares Out | 897.74M |
| EPS (ttm) | 15.29 |
| PE Ratio | 49.91 |
| Forward PE | 27.53 |
| Dividend | $6.00 (0.79%) |
| Ex-Dividend Date | Aug 15, 2025 |
| Volume | 1,808,364 |
| Open | 761.38 |
| Previous Close | 760.13 |
| Day's Range | 759.26 - 772.54 |
| 52-Week Range | 623.78 - 939.86 |
| Beta | 0.47 |
| Analysts | Strong Buy |
| Price Target | 972.00 (+27.36%) |
| Earnings Date | Oct 29, 2025 |
About LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]
Financial Performance
In 2024, Eli Lilly's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for LLY stock is "Strong Buy." The 12-month stock price target is $972.0, which is an increase of 27.36% from the latest price.
News
Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFs
The U.S. Food and Drug Administration's recent enforcement action against drug promotion is sending ETFs with exposure to weight-loss treatment manufacturers into question.
No more need for needles: A new generation of GLP-1 weight-loss drugs in pill form is coming closer
Makers of GLP-1 drugs, including Novo Nordisk and Eli Lilly, are close to releasing pills taken daily to help shed pounds as an alternative to weekly injections.
Novo Nordisk's Wegovy Outperforms Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke, And Death: Study
Novo Nordisk A/S NVO presented data from the STEER real-world study of evidence gathered from actual patient experiences at the European Society of Cardiology (ESC) Congress 2025.
Novo Nordisk Stock Jumps. New Ozempic Data for Seniors Beats Rival Eli Lilly Medicine.
In a study with people with Type 2 diabetes and cardiovascular disease, the drug Ozempic was shown to reduce the risk of heart attack, stroke and death by 23% compared with an older drug.
Market delayed in reaction to Novo Nordisk and Eli Lilly' s GLP-1 pills, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk competition in the GLP-1 pill space between Novo Nordisk and Eli Lilly.
Lilly's Mounjaro helps improve blood sugar control in children in late-stage trial
Eli Lilly's Mounjaro helped children and adolescents aged 10 to 17 years with type 2 diabetes manage their blood sugar better and lose weight, according to trial results presented at a medical meeting...
Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, reduced A1C by an average of 2.2% in a Phase 3 trial of children and adolescents with type 2 diabetes
In SURPASS-PEDS, Mounjaro met the primary and all key secondary endpoints at 30 weeks and showed sustained improvement in glycemic control and continued BMI reduction through the study's 52-week exten...
Eli Lilly: New Orforglipron Data In Focus As Commercial Business Outperforms
Eli Lilly and Company's hot streak of obesity and type 2 diabetes readouts ended in early August when we saw underwhelming top-line phase 3 results of orforglipron in obesity patients. Orforglipron lo...
Lilly's GLP-1 Pill Outperforms Older Novo Drug
Patients on Eli Lilly & Co.'s experimental diabetes pill lost more weight and had better blood sugar control than those on an older, approved rival from Novo Nordisk in the first head-to-head trial of...
Lilly's GLP-1 pill seen as superior in head-to-head trial with Novo's oral semaglutide
CNBC's Angelica Peebles joins 'Squawk on the Street' with the latest details about Eli Lilly's new drug trial.
Eli Lilly's New Diabetes Drug Shows Better Blood Sugar, Weight Loss Results Than Rival
The drug, which is meant to treat Type 2 diabetes, was compared with Novo Nordisk's oral semaglutide, and showed greater improvements in blood sugar levels, known as A1C, and greater weight loss.
GLP-1 drugs could save millions of lives — and spark a pension crisis
GLP-1 drugs are so powerful that, in 20 years, they can save millions from premature death, a leading insurance company says.
Lilly says its experimental GLP-1 pill better than Novo's Rybelsus in diabetes study
Eli Lilly on Wednesday said its experimental pill led to more weight loss and better control of blood sugar in patients with diabetes than oral semaglutide, the active ingredient in Danish rival Novo ...
Eli Lilly's obesity pill outperforms Novo Nordisk's oral drug in head-to-head diabetes trial
Eli Lilly said its experimental pill outperformed Novo Nordisk's own oral drug in the first head-to-head study comparing the two medicines in patients with Type 2 diabetes. Eli Lilly said its pill, o...
Lilly's oral GLP-1, orforglipron, superior to oral semaglutide in head-to-head trial
For the primary endpoint, orforglipron lowered A1C by 2.2% vs. 1.4% with oral semaglutide at the highest doses Participants taking the highest dose of orforglipron lost an average of 19.7 lbs (9.2%) v...
Lilly sees obesity drug leadership beyond US as it leans on consumer-focused strategy
Eli Lilly has established itself as the market leader in obesity drugs in Europe, Asia and the Middle East and expects to replicate its U.S. dominance globally, the company's international president t...
Eli Lilly cautious on using FDA fast-track voucher for weight loss pill
Eli Lilly's international president Patrik Jonsson said on Wednesday the company had little clarity on the U.S. Food and Drug Administration's new fast-track review process, cautioning it was too earl...
GSK and Eli Lilly are the latest multinational drugmakers to unveil plans to build more U.S. manufacturing plants and other operations, moves aimed partly at mitigating the threat of tariffs
GSK and Eli Lilly are the latest to unveil plans to add to manufacturing and increase other operations in America.
Lilly trial shows weight loss with experimental pill flattens over time
Eli Lilly's experimental GLP-1 pill helped people lose about 12% of their body weight, with weight loss plateauing for most patients in the 72-week trial, according to full study results presented at ...
Lilly CEO: U.K. has gone from biopharma leader to laggard
Lilly CEO Dave Ricks explains why pricing dynamics in the U.K. make it a very unattractive place for Lilly to invest.
Lilly's oral GLP-1, orforglipron, demonstrated meaningful weight loss and cardiometabolic improvements in complete ATTAIN-1 results published in The New England Journal of Medicine
The investigational once-daily oral pill led to an average weight loss of 27.3 lbs (12.4%) at the highest dose at week 72 in the Phase 3 study Orforglipron demonstrated significant improvements acros...
Trump Drug Ad Crackdown: FDA Warns Novo Nordisk, Eli Lilly, Hims
The Food and Drug Administration sent warning letters to dozens of drug companies— including popular telehealth firm Hims & Hers and pharmaceutical giants Eli Lilly and Novo Nordisk— demanding they co...
FDA Flags Eli Lilly's Weight-Loss Drug Video For Misleading Claims
The U.S. Food and Drug Administration (FDA) has determined that a promotional video featuring Zepbound and Mounjaro (tirzepatide), both produced by Eli Lilly And Co. LLY, is false or misleading.
Eli Lilly to invest $5B on Virginia plant amid Trump's pharma tariff threats
Pharmaceutical giant Eli Lilly expanded its Virginia facility investment plans to $5 billion from original $2.1 billion amid the Trump administration tariff threats on drug imports.